Skip to main content
OpenTrials
Completed

NCT Number: NCT03745547

An Exploratory, Observational, Non-interventional, Open Label, Remote Pilot Study to Assess Adherence in COPD Subjects

The purpose of this study is to monitor adherence to a clothing-attached breathing monitor, respiratory patterns, and activity levels in COPD patients, and correlate those respiratory patterns and activity levels with patient-reported symptoms and events. To achieve this purpose, Spire will collect data from a wearable monitor that participants attach to the participant's clothing, an associated smartphone application, and completion of weekly questions. The wearable monitor and the consumer smartphone application to be used are consumer products and currently available in the market.

This study does not include clinical intervention and no doctors will be involved in this study.

No clinical tests or office visits are included in this study. All data will be collected through an online survey tool and remotely through the wearable sensors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Moderate Chronic Obstructive Pulmonary Disease Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases Severe Chronic Obstructive Pulmonary Disease

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Spire, Inc.

San Francisco, California, 94110, United States

About this study

This is an exploratory, observational, non interventional, single-arm, open label, remote pilot study involving up to 150 self-reported COPD participants. Eligible participants will wear the Spire biophysiological health monitors for a period of 9 months while the participants report symptoms on a weekly basis via brief surveys. If and when participants incur a COPD-related exacerbation which results in a medication change after hospitalization or contact with a healthcare provider, participants will report this on the weekly surveys. When this survey is read by a study nurse, the nurse will follow up with the participant by phone to conduct a post-exacerbation phone screening. This data would provide context to inform how to correlate the biosensor-sensed physiological parameters with the exacerbation self-reported data. All study participants will be remotely distributed throughout the United States.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years old
  • Self-reported diagnosis of moderate to severe COPD
  • >=1 self-reported COPD-related hospitalization within the previous 12 months
  • Currently using an iPhone 6 or newer and willing to install the Spire smartphone app
  • Willing to wear Health Tags 80% of each 24 hour period and answer the email-based self-assessments weekly for the study duration
  • Willing to provide consent to participate and abide by study protocol for study duration (9 months)
  • Must be able to read and understand English
  • Access to Wi-Fi at home and at work, for at least 20 hours per day (and smartphone connected to Wi-Fi throughout the study duration)

Exclusion criteria

  • Diagnosed with another medical condition that may confound the respiratory symptoms of COPD (ex: cystic fibrosis, lung cancer, bronchiectasis, idiopathic pulmonary fibrosis, or chest wall deformities).
  • Diagnosed with any neurodegenerative disorder (e,g, Parkinson's, Alzheimer's or Epilepsy)
  • Pregnant at the time of study or expecting to become pregnant throughout the course of the study.

Treatment and study plan

Adherence to wearing a Spire wearable health monitor

Other

Participants will wear a Spire health monitor every day for 9 months and receive weekly emails with a short survey about the participant's condition and symptoms. If participants fail to respond to this email or Spire detects that a participant is not wearing the monitor, participants will be contacted by a nurse. While participants are wearing the monitor, Spire will make sure the sensors are collecting data but will not review the data in real time. If a participant's monitor stops sending data to Spire for more than 24 hours, the participant will be contacted. If the participant is unreachable for 10 days the participant's emergency contact will be contacted. If neither the participant nor the emergency contact is reachable over 24 days the participant will be removed from the study.

Primary outcomes

  1. Spire wearable health monitor physiological data collection

    Time frame: weekly email surveys and phone calls over a nine month period

    To evaluate the extent to which Spire wearable health monitor can capture viable data from COPD participants

Secondary outcomes

  1. Participant adherence

    Time frame: weekly email surveys and phone calls over a nine month period

    To evaluate the daily adherence to wearing the Spire wearable health monitor in COPD participants

Sponsors and collaborators

Lead sponsor

Spire, Inc.

Industry

Collaborators

  • ResMed

Registry information

Official study title

An Exploratory,Observational, Non-interventional, Open Label, Remote Pilot Study to Assess Adherence in Study Subjects With COPD

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Nov 19, 2018
Registry last updated
Jan 15, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.